| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 |
|---|---|---|---|---|---|---|---|---|---|
Operating expenses: | |||||||||
Research and development | |||||||||
18,587 | 17,640 | 14,709 | 11,749 | 8,039 | 4,943 | 0 | 0 | 0 | 0 |
General and administrative | |||||||||
9,244 | 9,087 | 8,629 | 7,491 | 5,887 | 3,672 | 0 | 0 | 0 | 0 |
Total operating expenses | |||||||||
27,831 | 26,727 | 23,338 | 19,240 | 13,926 | 8,615 | 0 | 0 | 0 | 0 |
Loss from operations | |||||||||
-27,831 | -26,727 | -23,338 | -19,240 | -13,926 | -8,615 | 0 | 0 | 0 | 0 |
Other (expense) income, net: | |||||||||
Interest expense | |||||||||
0 | - | 0 | - | - | 2,558 | 0 | 0 | 0 | 0 |
Interest income | |||||||||
1,213 | 1,391 | 1,380 | 1,083 | 733 | 340 | 0 | 0 | 0 | - |
Other expense, net | |||||||||
0 | - | 0 | 0 | - | - | - | - | - | - |
Change in fair value of Biocon anti-dilution right | |||||||||
- | - | - | - | - | 2,417 | 0 | 0 | 0 | 0 |
Total other (expense) income, net | |||||||||
344 | 1,127 | 314 | -2,687 | -3,697 | -4,635 | 0 | 0 | 0 | 0 |
Net loss | |||||||||
-27,487 | -25,600 | -23,024 | -21,927 | -17,623 | -13,250 | 0 | 0 | 0 | 0 |
Other comprehensive income, net: | |||||||||
Unrealized gain on available-for-sale securities, net | |||||||||
138 | 44 | 0 | 0 | 0 | - | - | - | - | - |
Foreign currency translation gain | |||||||||
0 | - | 0 | 0 | - | - | - | - | - | - |
Total other comprehensive income, net | |||||||||
425 | 16 | 0 | 0 | 0 | - | - | - | - | - |
Comprehensive loss | |||||||||
-27,062 | -25,584 | -22,944 | -21,840 | -17,574 | -13,245 | 0 | 0 | 0 | - |
Net loss per share, basic and diluted | |||||||||
-0.45 | -0.43 | -0.35 | -0.35 | -0.34 | -0.34 | -0.44 | -0.16 | -0.15 | -0.01 |
Weighted-average common shares outstanding, basic and diluted | |||||||||
17,562 | 17,383 | 17,376 | 17,376 | 17,376 | 16,258 | 11,078 | 10,715 | 10,708 | 10,708 |